Latest Breaking News On - Biohealth capital - Page 1 : vimarsana.com

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect.

United statesHarout semerjianDrug administrationAlliance for clinical trials in oncologyExchange commissionGlycomimetics incChinese national medical products administrationChief executive officerClinical trialsFirst quarterBreakthrough therapyFast trackBone marrowBiohealth capitalAnnual report

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Glycomimetics incConference callReport first quarterBiohealth capital

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Harout semerjianShantha tyavanagimattSickle cell disease research networkNational cancer instituteChinese national medical products administrationAlliance for clinical trials in oncologyGlycomimetics incExchange commissionConference callMimetics reports highlightsFinancial resultsFourth quarterFull yearChief executive officerClinical trialsSickle cell disease research

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To.

Glycomimetics incBiohealth capital

The twelve hottest biotech companies in the Boston area

Explore Boston's vibrant biotech landscape with twelve innovative companies leading the charge in life sciences research.

United kingdomUnited statesEli lillyPaul bernsJonathan smithSenda biosciencesMoma knowledgebaseVertex pharmaceuticalsBio pharma networking groupCystic fibrosis foundationHarvard biotech clubWave life sciencesNovo nordiskBiohealth capitalFlagship pioneeringLife edit